Hi! The T2B community recently reached a very exciting milestone: Our membership is now 1,000-strong! From 0 - 1000 in less than 18 months (we launched in October 2023). That’s pretty incredible. Beyond the sheer growth, I continue to be impressed with the experience we have within our community. About half of our members have more than 15 years of experience, and two-thirds have over a decade of expertise. And those comms rockstars have been absolutely vital in helping us develop the next generation of talent. Around a tenth of folks within T2B have fewer than three years of experience, and our veteran communicators have been inspirational in sharing advice to help our more junior members advance in their careers. Our community also covers every corner of the biopharma comms sector in terms of employers – and this balance has, remarkably, held steady since day 1:
You can find full details of (in-house) organizations represented by our membership here. As you can see, our membership is varied, which is why we’re already able to offer support, guidance, and development opportunities to biopharma comms pros from all areas of the industry. But we’re not stopping there. What’s next for T2B?Biopharma comms is a niche community. But that doesn’t mean it’s a small community. Think about all of the communicators supporting every aspect of the global life science ecosystem. That’s a lot of people – there are so many of us out there. (And that doesn’t even take into consideration emerging talent or people in adjacent industries who might be considering transitioning into our field in the near future.) So we want to reach even more folks. More like-minded individuals who are passionate about advancing our profession. And we’re making ourselves accountable by telling you that, in the future, we want to have a direct influence on there being:
How can you help?It doesn’t matter if you’re a comms veteran or a recent grad; part of a marketing team of one or a single cog in a huge department; or from a tiny start-up or a global organization. You are part of this, and we’ll be stronger with your support!
To all of you who have joined us and supported us on the journey so far: thank you. To those of you who will join us in the future; we can’t wait to have you on board. Lynnea |
Hi! The outcomes of the annual American Society of Clinical Oncology (ASCO) meeting will flood the media landscape with clinical updates, milestone announcements, and analyst notes. So biopharma comms pros and storytellers must understand how to stand out during one of healthcare’s most concentrated news moments. Enter the Q2 Media Minds Panel: Oncology Reporting and ASCO Coverage. “Top-Tier Perspective on ASCO and Beyond: How to Stand Out During Concentrated News Moments” is happening...
Hi! Last week, the T2B community tackled the topic of trust. In an intriguing and very candid Comm Convo led by speakers Kris Baum (former FDA, CDER), Mary Kosinski (FleishmanHillard), and Sarah Spencer (Vor Bio), we explored how the relationships we build shape our ability to lead, influence, and respond. With so many specific anecdotes and practical tips shared, it was hard to narrow down to just 10 key takeaways, but we managed it (barely!): Leverage science as your trust anchor. When...
Hi! We’re all about bringing together the most creative minds in biopharma in a bid to secure and enhance the future of our profession. One of the many ways we do this is through our roundtables, which are driven directly by members who specialize in, and are passionate about, key areas of biopharma communications. And the next discipline on that roster is patient advocacy and engagement. Everything you need to know about the Patient Advocacy and Engagement Roundtable This roundtable will...